8-K: Skye Bioscience Shifts Focus to Obesity Program After Glaucoma Trial Fails to Meet Primary Endpoint

Skye Bioscience discontinues its SBI-100 Ophthalmic Emulsion program after a Phase 2a trial failed to show a statistically significant improvement in intraocular pressure, redirecting resources to its obesity program.

Summary

• Skye Bioscience's Phase 2a clinical trial for SBI-100 Ophthalmic Emulsion, intended to treat glaucoma and ocular hypertension, did not meet its primary endpoint of lowering intraocular pressure.
• The trial involved 56 patients who received either 1.0% or 0.5% concentrations of SBI-100 OE, or a placebo, twice daily for 14 days.
• The company will discontinue the clinical development of SBI-100 OE and all related research and development, including its ophthalmology pipeline.
• Skye Bioscience will now focus its clinical development resources on its obesity program, specifically the development of Nimacimab.
• A Phase 2 clinical trial for Nimacimab in obesity is expected to begin in Q3 2024.
• The company's cash runway has been extended into 2027.

Sentiment

Score: 4

Explanation: The document contains negative news regarding the failure of the glaucoma trial, but the company is pivoting to a potentially more lucrative market. The sentiment is therefore negative overall but with a positive outlook.

Positives

• The company is redirecting resources to its obesity program, which has a potentially larger market.
• The Phase 2a trial of SBI-100 OE showed the drug was safe, with no early discontinuations due to adverse events.
• The company has extended its cash runway into 2027.
• The company is planning a Phase 2 trial for Nimacimab in obesity, including combination arms with a GLP-1R agonist.

Negatives

• The Phase 2a trial of SBI-100 Ophthalmic Emulsion failed to meet its primary endpoint.
• The company is discontinuing the development of SBI-100 OE and its ophthalmology pipeline, which represents a setback in that area.
• The company is incurring costs associated with the failed trial.

Risks

• The company's future success is now heavily reliant on the success of its obesity program.
• There is uncertainty regarding the results of future testing and development efforts for Nimacimab.
• The company operates in a rapidly changing environment, and new risks may emerge.
• The company's capital resources may be insufficient to fund all development programs.

Future Outlook

The company will focus on advancing Nimacimab through clinical trials, with data expected in 2025. They aim to broaden their metabolic clinical pipeline and believe Nimacimab has the potential to address the need for higher-quality, sustainable weight loss.

Management Comments

• Tu Diep, Skyes Chief Development Officer, stated that the results of the Phase 2a clinical trial of SBI-100 OE did not meet their pre-set criteria for continuation.
• Punit Dhillon, Skyes CEO and Chair, said that the company will now focus 100% of its efforts on broadening its metabolic clinical pipeline.
• Punit Dhillon believes that Nimacimabs unique mechanism of peripheral CB1 inhibition positions it to potentially contribute to the need for higher-quality, sustainable weight loss.

Industry Context

The shift in focus to obesity reflects a broader trend in the pharmaceutical industry towards developing treatments for metabolic diseases. The company is positioning Nimacimab as a differentiated option in the anti-obesity therapeutic landscape, which is currently dominated by incretin-based therapies.

Comparison to Industry Standards

• The failure of the SBI-100 OE trial highlights the challenges in developing new treatments for glaucoma, where many companies have faced setbacks.
• The move to focus on obesity aligns with the current market interest in weight loss drugs, with companies like Eli Lilly and Novo Nordisk leading the way with GLP-1 agonists.
• Nimacimab's approach as a CB1 inhibitor is different from the GLP-1 agonists, potentially offering a new mechanism for weight loss.
• The company's decision to include combination arms with a GLP-1R agonist in the Nimacimab trial is a common strategy to enhance efficacy, similar to approaches taken by other companies in the obesity space.

Stakeholder Impact

• Shareholders may react negatively to the failure of the glaucoma trial, but positively to the focus on the obesity program.
• Employees involved in the ophthalmology program may be affected by the discontinuation of the program.
• Patients with glaucoma and ocular hypertension will not have access to SBI-100 OE as a potential treatment option.
• Patients with obesity may benefit from the development of Nimacimab.

Next Steps

• The company will discontinue the clinical development of SBI-100 OE.
• The company will focus on the clinical development of Nimacimab for obesity.
• A Phase 2 clinical trial for Nimacimab in obesity is expected to begin in Q3 2024.
• The company will evaluate the full data set from the SBI-100 OE trial and intend to publish findings.
• The company will share updates on the Nimacimab clinical program and advance it through to data in 2025.

Key Dates

Keywords

Skye Bioscience, SBI-100 Ophthalmic Emulsion, Nimacimab, glaucoma, ocular hypertension, obesity, clinical trial, intraocular pressure, metabolic program, CB1 inhibitor